Table 2 Clinical characteristics of RA patients according to tertiles of SII.
Characteristics | Total | Tertiles of SII | P value | ||
|---|---|---|---|---|---|
T1 111.70–555.90.70.90 | T2 556.40–933.60.40.60 | T3 993.70–3241.10.70.10 | |||
N | 997 | 332 | 331 | 334 | |
Age (year) | 57.66 (12.82) | 56.61 (12.85) | 57.72 (12.95) | 58.63 (12.63) | 0.127 |
Female, n (%) | 777 (77.93%) | 285 (85.84%) | 259 (78.25%) | 233 (69.76%) | < 0.001 |
BMI (kg/m2) | 23.96 (3.49) | 23.90 (3.45) | 24.13 (3.59) | 23.87 (3.44) | 0.573 |
DD (month) | 48.00 (12.00–132.00.00.00) | 60.00 (12.00–144.00.00.00) | 48.00 (12.00–144.00.00.00) | 42.00 (10.00–120.00.00.00) | 0.219 |
Smoking, n (%) | 55 (5.52%) | 15 (4.52%) | 18 (5.44%) | 22 (6.59%) | 0.503 |
Drinking, n (%) | 18 (1.81%) | 4 (1.20%) | 8 (2.42%) | 6 (1.80%) | 0.503 |
Hypertension, n (%) | 323 (32.40%) | 87 (26.20%) | 102 (30.82%) | 134 (40.12%) | < 0.001 |
DM, n (%) | 93 (9.33%) | 28 (8.43%) | 30 (9.06%) | 35 (10.48%) | 0.649 |
CHD, n (%) | 69 (6.92%) | 27 (8.13%) | 17 (5.14%) | 25 (7.49%) | 0.278 |
WBC (*109/L) | 6.52 (2.18) | 5.16 (1.52) | 6.57 (1.80) | 7.81 (2.27) | < 0.001 |
Neut (*109/L) | 4.22 (1.81) | 2.78 (0.99) | 4.26 (1.20) | 5.62 (1.83) | < 0.001 |
Lymph (*109/L) | 1.63 (0.59) | 1.77 (0.62) | 1.64 (0.59) | 1.48 (0.52) | < 0.001 |
RBC (*1012/L) | 3.88 (0.49) | 3.88 (0.47) | 3.89 (0.50) | 3.88 (0.52) | 0.883 |
Hb (g/L) | 111.07 (17.14) | 112.85 (15.74) | 111.95 (17.47) | 108.44 (17.85) | 0.002 |
PLT (*109/L) | 291.96 (90.93) | 231.55 (61.73) | 283.96 (70.14) | 359.93 (87.94) | < 0.001 |
ESR (mm/H) | 56.00 (33.00–86.00) | 38.00 (24.00–61.00) | 56.00 (35.00–84.00) | 79.00 (52.00–104.00.00.00) | < 0.001 |
CRP (mg/L) | 26.01 (7.13–48.02) | 7.95 (2.45–24.15) | 26.50 (7.96–40.94) | 46.84 (28.32–78.35) | < 0.001 |
RF (IU/mL) | 161.80 (47.77–335.83.77.83) | 159.70 (48.12–297.03.12.03) | 136.10 (42.10–297.40.10.40) | 206.60 (51.90–439.60.90.60) | 0.002 |
ACPA positive n (%) | 898 (90.89%) | 291 (89.54%) | 302 (91.79%) | 305 (91.32%) | 0.573 |
APF positive, n (%) | 782 (81.04%) | 249 (79.30%) | 260 (80.75%) | 273 (82.98%) | 0.486 |
AKA positive, n (%) | 723 (75.00%) | 227 (72.52%) | 242 (75.16%) | 254 (77.20%) | 0.391 |
CDAI | 17.80 (5.43) | 15.14 (5.10) | 18.03 (5.07) | 19.97 (5.03) | < 0.001 |
SDAI | 21.48 (8.42) | 16.96 (6.53) | 21.04 (6.90) | 25.99 (8.95) | < 0.001 |
DAS28ESR | 5.09 (0.97) | 4.60 (1.00) | 5.16 (0.88) | 5.50 (0.80) | < 0.001 |
DAS28CRP | 4.39 (0.93) | 3.86 (0.91) | 4.46 (0.81) | 4.84 (0.80) | < 0.001 |
NSAIDs, n (%) | 510 (51.15%) | 174 (52.41%) | 180 (54.38%) | 156 (46.71%) | 0.120 |
Glucocorticoids, n (%) | 107 (10.73%) | 31 (9.34%) | 35 (10.57%) | 41 (12.28%) | 0.469 |
Methotrexate, n (%) | 204 (20.46%) | 72 (21.69%) | 76 (22.96%) | 56 (16.77%) | 0.112 |
Leflunomide, n (%) | 195 (19.56%) | 80 (24.10%) | 64 (19.34%) | 51 (15.27%) | 0.016 |
Types of cDMARDs, n (%) | 0.008 | ||||
0 | 518 (51.96%) | 147 (44.28%) | 171 (51.66%) | 200 (59.88%) | |
1 | 357 (35.81%) | 134 (40.36%) | 121 (36.56%) | 102 (30.54%) | |
2 | 116 (11.63%) | 49 (14.76%) | 37 (11.18%) | 30 (8.98%) | |
3 | 6 (0.60%) | 2 (0.60%) | 2 (0.60%) | 2 (0.60%) | |
bDMARDs, n (%) | 42 (4.21%) | 19 (5.72%) | 12 (3.63%) | 11 (3.29%) | 0.239 |
tsDMARDs, n (%) | 23 (2.31%) | 9 (2.71%) | 8 (2.42%) | 6 (1.80%) | 0.725 |
